Preparing to Launch: What You Need to Know (But No One Ever Told You) About Entering the Oncology Workforce

As fellows prepare to enter the oncology workforce, they will be faced with many obstacles and situations for which the standard medical education curriculum did not prepare them. From networking and interviewing, to working with other members of the interprofessional oncology care team, to creating work/life balance, understanding how to navigate these situations is essential to career development and success which ultimately impacts patient care.

Target Audience

This program is designed to meet the educational needs of second- and third-year medical, surgical, and radiation oncology fellows.

Learning Objectives

Following this program, participants should be able to:

  • Discuss how to align your passions and aspirations to discover your ideal career path.
  • Incorporate practical skills that can be used to enhance career development and progression.
  • Describe common obstacles and pitfalls that may be faced in early career.
  • Explain key factors that will support a successful transition from fellow to attending physician.
Additional information
Supporters: 

Supported by educational grants from AstraZeneca; BeiGene; Coherus BioSciences; Genentech, a member of the Roche Group; and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. Supported by independent medical educational grants from Boehringer Ingelheim Pharmaceuticals, Inc.; GSK; and Regeneron Pharmaceuticals, Inc.

Course summary
Available credit: 
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 Participation
Course opens: 
06/15/2024
Course expires: 
03/01/2025
Cost:
$0.00

Moderator

Anthony J. Olszanski, MD, RPh
Fox Chase Cancer Center

Panelists

Cynthia S. Anderson, MD
Baptist Health MD Anderson

Kimberley Lee, MD, MHS
Moffitt Cancer Center

John W. Sweetenham, MD
UT Southwestern Simmons Comprehensive Cancer Center

 

NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 

Definitions  

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers  

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Faculty, Moderator, and Planner Disclosures

The faculty listed below have no relevant financial relationship(s) with ineligible companies to disclose. 

Cynthia S. Anderson, MD
Karen Kanefield
Wui-Jin Koh, MD
Kimberley Lee, MD, MHS
Randall A. Oyer, MD
John W. Sweetenham, MD

The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated. 

Timothy Kubal, MD, MBA
Apellis Pharmaceuticals: Scientific Advisor

Anthony J. Olszanski, MD, RPh
Bristol Myers Squibb: Scientific Advisor
InstilBio: Scientific Advisor
Merck & Co., Inc.: Scientific advisor
Novartis Pharmaceuticals Corporation: Scientific Advisor
Oncosec Immunotherapies: Scientific Advisor
Pfizer Inc.: Honoraria
Replimune: Scientific Advisor

NCCN Staff Disclosures

The planners listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.

Crystal Denlinger, MD, FACP 
2seventy bio: Grant/Research Support
AbbVie, Inc.: Grant/Research Support
Bluebird bio: Grant/Research Support
Bristol Myers Squibb: Grant/Research Support
Eli Lilly and Company: Grant/Research Support
Genentech, Inc: Grant/Research Support
GSK: Grant/Research Support
Pfizer Inc: Grant/Research Support
sanofi-aventis U.S.: Grant/Research Support

None of the other planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

image

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
NCCN designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Available Credit

  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 Participation

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing